BioNxt Solutions Advances Multiple Sclerosis Treatment into Eurasian Markets

BioNxt Solutions enters exclusive talks to commercialize its sublingual Cladribin film for MS in the Eurasian region, backed by new patents and a potential market of over 200 million people.

BioNxt Solutions has taken a significant step toward commercializing its innovative Cladribin film for patients with Multiple Sclerosis. The company announced on March 17, 2026, the signing of a non-binding Letter of Intent (LOI) concerning the exclusive rights to market the product in one or more member states of the Eurasian Patent Organization (EAPO).

A Patient-Centric Neurological Treatment

At the core of this development is BioNxt's sublingual oral dissolving film (ODF) formulation of Cladribin. This delivery method is specifically engineered for rapid absorption under the tongue, addressing a key need for MS patients who experience difficulty swallowing conventional tablets. The technology represents a broader shift within neurology toward more patient-friendly drug administration formats.

To support its regulatory pathway, BioNxt is concurrently preparing a human bioequivalence study for its Cladribin program. This research is a required component for securing future marketing approvals from health authorities.

Exclusive Negotiations and Patent Protection

The newly signed LOI initiates a 60-day period of exclusive negotiations. During this window, the parties will work to finalize the specific commercial terms for bringing the ODF to the Eurasian region. The potential market is substantial, encompassing a population exceeding 200 million people across eight EAPO member states.

This opportunity is underpinned by robust intellectual property. The foundation is EAPO Patent No. 051510, which was granted in November 2025 and provides protection until at least 2043. In a complementary move, the European Patent Office published European Patent No. 4539857 on March 11, 2026. This patent offers protection in up to 39 contracting states of the European Patent Convention, also lasting until at least June 2043.

The Path Forward

The coming two months will be decisive for BioNxt Solutions. The exclusive negotiation phase will determine whether this preliminary agreement matures into a binding commercial contract. Success would mark a major expansion of the company's reach, providing a route to bring its specialized MS therapy to a vast new patient population in Eurasia.